You are here: Industry Insights > Ensifentrine

News List

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China prnasia
June 10, 2021
Verona Pharma plc and Nuance Pharma Limited, today announce that the companies have entered into an agreement granting Nuance Pharma, a Shanghai-based specialty pharmaceutical company, the rights to develop and commercialize ensifentrine in ...
Trial to evaluate inhaled COVID-19 therapy finishes enrolment europeanpharmaceuticalreview
January 19, 2021
The pilot study will determine whether an inhaled formulation of ensifentrine can expedite the recovery of patients hospitalised with COVID-19.
Verona begins pilot study of potential COVID-19 inhaler pharmatimes
September 17, 2020
Verona Pharma has kicked off a pilot study to investigate the efficacy and safety of ensifentrine delivered via pressurised metered-dose inhaler (pMDI) formulation in patients hospitalised with COVID-19.
Inhaled ensifentrine will be assessed in hospitalised patients pharmatimes
September 08, 2020
Verona Pharma has kicked off a pilot study to investigate the efficacy and safety of ensifentrine delivered via pressurised metered-dose inhaler (pMDI) formulation in patients hospitalised with COVID-19.
Verona progresses PhII trial of COPD inhaler pharmatimes
August 19, 2020
Verona Pharma is progressing a Phase II trial of new inhaler formulation of ensifentrine following a coronavirus pandemic-induced pause.
Ensifentrine improves lung function in COPD patients pharmatimes
April 01, 2020
Verona Pharma has reported positive efficacy and safety data from ensifentrine in chronic obstructive pulmonary disease (COPD) patients.